Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 10/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 11/20 | 0.40 |
| ▸ | ACP3 | P15309 | 1/20 | 0.38 |
| ▸ | CCR2 | P41597 | 1/20 | 0.37 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30174859 | 1.00 | OPRM1 (0.46) | OPRM1OPRD1OPRK1OPRL1SLC6A4 | |
| SCHEMBL25518294 | 0.89 | SLC6A4 (0.40) | OPRM1OPRD1OPRK1OPRL1SLC6A4 | |
| SCHEMBL30174956 | 0.89 | SLC6A4 (0.40) | OPRM1OPRD1OPRK1OPRL1SLC6A4 | |
| SCHEMBL31332725 | 0.79 | CCR2 (0.44) | OPRM1OPRD1OPRK1OPRL1SLC6A4 | |
| SCHEMBL20684979 | 0.75 | SLC6A3 (0.45) | OPRM1OPRD1OPRK1OPRL1SLC6A4 | |
| SCHEMBL17684783 | 0.75 | SLC6A2 (0.57) | OPRM1OPRD1OPRK1OPRL1SLC6A4 | |
| SCHEMBL17684445 | 0.71 | SLC6A2 (0.44) | OPRM1OPRD1OPRK1OPRL1SLC6A4 | |
| SCHEMBL6225449 | 0.69 | ACP3 (0.50) | SLC6A4SLC6A2ACP3 | |
| SCHEMBL424623 | 0.69 | ACP3 (0.50) | SLC6A4SLC6A2ACP3 | |
| SCHEMBL29403128 | 0.69 | ACP3 (0.50) | SLC6A4SLC6A2ACP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159453-A1 | INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | COCRYSTAL PHARMA, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230159453-A1 | INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | COCRYSTAL PHARMA, INC. | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159453-A1 | INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | VIM, ACE, ACE2 | OPRM1 1969/4885OPRD1 2473/4885OPRK1 1788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.